Company news

Arrowhead Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street

August 7, 2024

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results

July 23, 2024

Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial

June 24, 2024

Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE

June 23, 2024

Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome

June 2, 2024

Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences

May 30, 2024

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia

May 28, 2024

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia

May 27, 2024

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma

May 19, 2024

Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results

May 8, 2024

Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma

May 1, 2024

Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences

April 28, 2024

Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars

April 25, 2024

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results

April 23, 2024

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

April 23, 2024

Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

April 6, 2024

Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data

March 24, 2024

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

March 7, 2024

Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences

March 3, 2024

Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results

February 5, 2024

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results

January 21, 2024

Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million

January 4, 2024

Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock

January 2, 2024

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease

December 20, 2023

Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 19, 2023

Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results

November 28, 2023

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

November 27, 2023

Arrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference

November 20, 2023

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results

November 15, 2023

Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

November 12, 2023

Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare Conference

November 5, 2023

Arrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023

November 1, 2023

Arrowhead Pharmaceuticals to Participate in Upcoming October 2023 Conferences

October 2, 2023

Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023

September 10, 2023

Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences

August 31, 2023

Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results

August 6, 2023

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Third Quarter Results

July 23, 2023

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy

July 16, 2023

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1

June 26, 2023

Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease

June 23, 2023

Arrowhead Pharmaceuticals to Participate in Upcoming June 2023 Conferences

June 5, 2023

Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics

May 31, 2023

Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH

May 22, 2023

Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

May 15, 2023

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences

May 14, 2023

Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results

May 1, 2023

Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect

April 24, 2023

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results

April 17, 2023

Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics

April 11, 2023

First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead

April 3, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.